Metsera, Inc.
MTSR
Hisse Senetlerindeki Sıralama
#2572
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Hisse Fiyatı
$70.50
Son senkronizasyon: 2025-11-14
Piyasa Değeri
$7.33B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
33.60%
Ülke
US
Ticaret Metsera, Inc. (MTSR)
Kategori
Healthcare
Metsera, Inc. (MTSR) için temettü verimi geçmişi
Metsera, Inc. (hisse sembolü: MTSR) temettü verimi (TTM) 2026 itibariyle: 0
Son 5 yılın ortalama temettü verimi: 0.00%
Son 5 yılın ortalama temettü verimi: 0.00%
Metsera, Inc. (MTSR) için 2023 - 2026 arası temettü verimi geçmişi
Her yılın sonunda temettü verimi (TTM)
| Yıl | Temettü Verimi | Değiştir |
|---|---|---|
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
Benzer şirketler veya rakiplerin temettü verimi (TTM)
| Şirket | Temettü Verimi | Ülke |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
NL
|
|
| 0.00% |
CH
|
